Monica Balzarotti

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Andrés JM Ferreri, Michele Reni, Marco Foppoli et al. · The Lancet · 2009 · 662 citations · Full text

Medicine, Oncology, Pharmacology +10

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 599 citations · Full text

Medicine, Immunology, Oncology +12

Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

Emanuele Zucca, Annarita Conconi, Tariq I. Mughal et al. · Journal of Clinical Oncology · 2002 · 445 citations · Full text

Medicine, Oncology, Chemotherapy +14

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2017 · 381 citations · Full text

Medicine, Immunology, Oncology +17

First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial

Umberto Vitolo, Annalisa Chiappella, Andrés J.M. Ferreri et al. · Journal of Clinical Oncology · 2011 · 239 citations · Full text

Medicine, Immunology, Oncology +13